Prognostic Index for Critically Ill Allogeneic Transplantation Patients

Area of Science:

• Hematology
• Critical Care Medicine
• Oncology

Background:

• Outcomes for allogeneic hematopoietic stem cell transplantation (Allo-SCT) patients in intensive care are generally poor.
• Existing prognostic tools have limited value for selecting critically ill Allo-SCT patients for intensive care.
• Improved patient selection can reduce healthcare costs and burdens on patients and families.

Purpose of the Study:

• To develop and validate a novel prognostic index specifically for critically ill Allo-SCT patients.
• To enhance the accuracy of mortality prediction in this vulnerable patient population.
• To provide a more effective tool for intensive care unit (ICU) admission decisions.

Main Methods:

• A prognostic index, PICAT (Prognostic Index for Intensive Care after Allogeneic Hematopoietic Stem Cell Transplantation), was developed using data from 656 Allo-SCT patients admitted to the ICU.
• Multivariable regression models were used to identify key predictors of hospital mortality.
• The model with the highest Area Under the Receiver Operating Curve (AUC) in a test set was selected.

Main Results:

• The PICAT model demonstrated strong predictive accuracy with an AUC of 0.80 for hospital mortality.
• PICAT significantly outperformed traditional scoring systems like APACHE II (AUC 0.61) and SOFA (AUC 0.72).
• PICAT scores correlated with varying hospital mortality rates (34%-91%) and median overall survival (0.30-7.59 months).

Conclusions:

• PICAT is a well-calibrated and accurate prognostic tool for predicting mortality in critically ill Allo-SCT patients.
• The PICAT index offers superior performance compared to APACHE II and SOFA scores in this specific patient group.
• PICAT can aid in optimizing the selection of Allo-SCT patients for intensive care, potentially improving resource allocation and patient outcomes.